Trial profile.
MSSA
CONSORT diagram indicating participant numbers and disposition throughout the course of the trail. *51 patients had more than one exclusion criterion.The primary endpoint was treatment success at day 7 after randomization, a composite endpoint comprising the following criteria: patient alive, stable or with improved quick sequential organ failure assessment (qSOFA) score, afebrile and with negative blood cultures for MSSA. In a planned interim analysis performed when half of the sample size had been recruited, an independent committee blinded to treatment allocation recommended stopping randomization because its members estimated that it was highly unlikely that statistically significant superiority of the combination therapy would be achieved with full enrollment (data regarding this decision are provided in the 